Pharmacogenetics of HIV therapy: State of the art in Latin American countries

Detalhes bibliográficos
Autor(a) principal: Velozo,Camila de Almeida
Data de Publicação: 2022
Outros Autores: Lamarão,Flávia Rachel Moreira, Alvarado-Arnez,Lucia Elena, Cardoso,Cynthia Chester
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Genetics and Molecular Biology
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400107
Resumo: Abstract The use of combined antiretroviral therapy (cART) has resulted in a remarkable reduction in morbidity and mortality of people living with HIV worldwide. Nevertheless, interindividual variations in drug response often impose a challenge to cART effectiveness. Although personalized therapeutic regimens may help overcome incidence of adverse reactions and therapeutic failure attributed to host factors, pharmacogenetic studies are often restricted to a few populations. Latin American countries accounted for 2.1 million people living with HIV and 1.4 million undergoing cART in 2020-21. The present review describes the state of art of HIV pharmacogenetics in this region and highlights that such analyses remain to be given the required relevance. A broad analysis of pharmacogenetic markers in Latin America could not only provide a better understanding of genetic structure of these populations, but might also be crucial to develop more informative dosing algorithms, applicable to non-European populations.
id SBG-1_fe608c16474751296999bfacddaaf715
oai_identifier_str oai:scielo:S1415-47572022000400107
network_acronym_str SBG-1
network_name_str Genetics and Molecular Biology
repository_id_str
spelling Pharmacogenetics of HIV therapy: State of the art in Latin American countriesHIVLatin AmericapharmacogeneticsCYP2B6HLA-B*57:01Abstract The use of combined antiretroviral therapy (cART) has resulted in a remarkable reduction in morbidity and mortality of people living with HIV worldwide. Nevertheless, interindividual variations in drug response often impose a challenge to cART effectiveness. Although personalized therapeutic regimens may help overcome incidence of adverse reactions and therapeutic failure attributed to host factors, pharmacogenetic studies are often restricted to a few populations. Latin American countries accounted for 2.1 million people living with HIV and 1.4 million undergoing cART in 2020-21. The present review describes the state of art of HIV pharmacogenetics in this region and highlights that such analyses remain to be given the required relevance. A broad analysis of pharmacogenetic markers in Latin America could not only provide a better understanding of genetic structure of these populations, but might also be crucial to develop more informative dosing algorithms, applicable to non-European populations.Sociedade Brasileira de Genética2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400107Genetics and Molecular Biology v.45 n.3 suppl.1 2022reponame:Genetics and Molecular Biologyinstname:Sociedade Brasileira de Genética (SBG)instacron:SBG10.1590/1678-4685-gmb-2022-0120info:eu-repo/semantics/openAccessVelozo,Camila de AlmeidaLamarão,Flávia Rachel MoreiraAlvarado-Arnez,Lucia ElenaCardoso,Cynthia Chestereng2022-09-27T00:00:00Zoai:scielo:S1415-47572022000400107Revistahttp://www.gmb.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||editor@gmb.org.br1678-46851415-4757opendoar:2022-09-27T00:00Genetics and Molecular Biology - Sociedade Brasileira de Genética (SBG)false
dc.title.none.fl_str_mv Pharmacogenetics of HIV therapy: State of the art in Latin American countries
title Pharmacogenetics of HIV therapy: State of the art in Latin American countries
spellingShingle Pharmacogenetics of HIV therapy: State of the art in Latin American countries
Velozo,Camila de Almeida
HIV
Latin America
pharmacogenetics
CYP2B6
HLA-B*57:01
title_short Pharmacogenetics of HIV therapy: State of the art in Latin American countries
title_full Pharmacogenetics of HIV therapy: State of the art in Latin American countries
title_fullStr Pharmacogenetics of HIV therapy: State of the art in Latin American countries
title_full_unstemmed Pharmacogenetics of HIV therapy: State of the art in Latin American countries
title_sort Pharmacogenetics of HIV therapy: State of the art in Latin American countries
author Velozo,Camila de Almeida
author_facet Velozo,Camila de Almeida
Lamarão,Flávia Rachel Moreira
Alvarado-Arnez,Lucia Elena
Cardoso,Cynthia Chester
author_role author
author2 Lamarão,Flávia Rachel Moreira
Alvarado-Arnez,Lucia Elena
Cardoso,Cynthia Chester
author2_role author
author
author
dc.contributor.author.fl_str_mv Velozo,Camila de Almeida
Lamarão,Flávia Rachel Moreira
Alvarado-Arnez,Lucia Elena
Cardoso,Cynthia Chester
dc.subject.por.fl_str_mv HIV
Latin America
pharmacogenetics
CYP2B6
HLA-B*57:01
topic HIV
Latin America
pharmacogenetics
CYP2B6
HLA-B*57:01
description Abstract The use of combined antiretroviral therapy (cART) has resulted in a remarkable reduction in morbidity and mortality of people living with HIV worldwide. Nevertheless, interindividual variations in drug response often impose a challenge to cART effectiveness. Although personalized therapeutic regimens may help overcome incidence of adverse reactions and therapeutic failure attributed to host factors, pharmacogenetic studies are often restricted to a few populations. Latin American countries accounted for 2.1 million people living with HIV and 1.4 million undergoing cART in 2020-21. The present review describes the state of art of HIV pharmacogenetics in this region and highlights that such analyses remain to be given the required relevance. A broad analysis of pharmacogenetic markers in Latin America could not only provide a better understanding of genetic structure of these populations, but might also be crucial to develop more informative dosing algorithms, applicable to non-European populations.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400107
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400107
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1678-4685-gmb-2022-0120
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Genética
publisher.none.fl_str_mv Sociedade Brasileira de Genética
dc.source.none.fl_str_mv Genetics and Molecular Biology v.45 n.3 suppl.1 2022
reponame:Genetics and Molecular Biology
instname:Sociedade Brasileira de Genética (SBG)
instacron:SBG
instname_str Sociedade Brasileira de Genética (SBG)
instacron_str SBG
institution SBG
reponame_str Genetics and Molecular Biology
collection Genetics and Molecular Biology
repository.name.fl_str_mv Genetics and Molecular Biology - Sociedade Brasileira de Genética (SBG)
repository.mail.fl_str_mv ||editor@gmb.org.br
_version_ 1752122390658154496

Registros relacionados